Metabolic Evaluation of Non–Small Cell Lung Cancer Patient–Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response
暂无分享,去创建一个
U. Pastorino | G. Sozzi | R. Moresco | S. Valtorta | L. Roz | M. Tortoreto | I. Raccagni | M. Moro | G. Bertolini | Giovanna Prisinzano
[1] G. Giaccone,et al. Refining the treatment of NSCLC according to histological and molecular subtypes , 2015, Nature Reviews Clinical Oncology.
[2] L. Mariani,et al. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis. , 2015, Cancer research.
[3] U. Pastorino,et al. Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] R. Herbst,et al. Lung Cancer in the Era of Precision Medicine , 2015, Clinical Cancer Research.
[5] A. Adjei,et al. New strategies to develop new medications for lung cancer and metastasis , 2015, Cancer and Metastasis Reviews.
[6] K. Shaw,et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. , 2015, Cancer letters.
[7] H. Klomp,et al. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. , 2014, World journal of radiology.
[8] A. Shaw,et al. Molecular Pathways Molecular Pathways : Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies , 2014 .
[9] Julia Schüler,et al. Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells , 2014, Proceedings of the National Academy of Sciences.
[10] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[11] C. Park,et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. , 2013, Lung cancer.
[12] Aik Choon Tan,et al. Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.
[13] M. Tian,et al. Molecular Imaging in Tracking Tumor Stem-Like Cells , 2012, Journal of biomedicine & biotechnology.
[14] U. Pastorino,et al. Patient-Derived Xenografts of Non Small Cell Lung Cancer: Resurgence of an Old Model for Investigation of Modern Concepts of Tailored Therapy and Cancer Stem Cells , 2012, Journal of biomedicine & biotechnology.
[15] P. Ward,et al. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.
[16] K. Togashi,et al. Relationship between 18F-Fluorodeoxyglucose Accumulation and KRAS/BRAF Mutations in Colorectal Cancer , 2012, Clinical Cancer Research.
[17] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[18] O. Thews,et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. , 2011, Cancer research.
[19] M. Hidalgo,et al. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.
[20] T. Beckers,et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. , 2011, European journal of cancer.
[21] S. Ivy,et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.
[22] T. Mak,et al. Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.
[23] Y. Fujibayashi,et al. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. , 2010, Nuclear medicine and biology.
[24] S. Lam,et al. Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy , 2010, Clinical Cancer Research.
[25] F. Fazio,et al. Fluorodeoxyglucose Uptake Measured by Positron Emission Tomography and Standardized Uptake Value Predicts Long-Term Survival of CT Screening Detected Lung Cancer in Heavy Smokers , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] L. Mariani,et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.
[27] Chin-Lee Wu,et al. mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome , 2009, Proceedings of the National Academy of Sciences.
[28] Claude Deschamps,et al. The role of positron emission tomography in the management of non-small cell lung cancer. , 2009, Canadian journal of surgery. Journal canadien de chirurgie.
[29] Y. Fujibayashi,et al. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. , 2009, Nuclear medicine and biology.
[30] Giovanni Parmigiani,et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.
[31] Michael Becker,et al. Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers , 2008, Clinical Cancer Research.
[32] M. Biffoni,et al. Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.
[33] Y. Nishiyama,et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[34] Eva Forssell-Aronsson,et al. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. , 2007, Cancer research.
[35] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[36] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[37] R. Bertorelle,et al. VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells. , 2015, Cancer research.
[38] H. Hansen,et al. Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.